Posts tagged ‘Translational Medicine Consultant’
March 25th, 2011
Mice seem to get bad PR; there’s far more people that like cats……..So in the interests of fair balance, we’d like to draw attention to the increasing importance of preclinical mouse models in cancer drug development.
Pieter Droppert on Biotech Strategy Blog discusses how innovations in translational medicine, and improved mouse models of human cancer are having a major impact on bringing new cancer drugs to market.
So, time for some good thoughts about mice (with apologies to cat lovers out there).
March 7th, 2011
Sally Church on Pharma Strategy Blog, today discusses personalized therapy for prostate cancer, and the extent to which this is possible?
Following the recent AACR special conference on the PI3K-mTor pathway, Sally shares some of the key learnings for oncology drug development and translational medicine.
Her opinion is that “in the future, targeted therapies may evolve in smaller subsets of disease with more logical or double or even triple combinations.”
In an insightful post on Pharma Strategy Blog, Sally discusses recent research that suggests there may be a market opportunity for anti-SPINK1 monoclonal antibodies that target a subset of prostate cancer patients. Breathtaking stuff!
March 5th, 2011
Both brainstem gliomas and glioblastomas have poor prognosis, which raises the importance of translational medical research that could lead to new targeted therapies.
Research by Phillips et al, has shown that Akt and Notch signaling are hallmarks of poor prognosis, suggesting that identification of molecular subtypes may be useful in the development of new therapies.
January 13th, 2011
Published by Sally Church on Pharma Strategy Blog